Proton-Pump Inhibitors and Osteoporotic Fractures

PPI use was associated with spine and forearm or wrist fractures, but not hip fractures, in postmenopausal women.

Prior epidemiological studies have suggested an association between proton-pump inhibitor (PPI) use and hip fractures (JW Gastroenterol Oct 3 2008 and JW Gastroenterol Jan 5 2007). The mechanism for this result is thought to be related to long-term suppression of gastric acid, which can reduce intestinal absorption of calcium and thereby impair bone homeostasis. To further examine fracture risks associated with PPI use, investigators conducted a prospective, population-based study involving 130,487 postmenopausal women (age range, 50–79) with no history of hip fracture.

Multivariate analysis showed that, during a mean follow-up of 7.8 years (>1 million patient-years of follow-up), PPI use was associated with the following osteoporotic effect…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors